Yoshinobu Nakamaru

Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): A highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

Tomohiro Yoshida, Fumihiko Akahoshi, Hiroshi Sakashita et al. · Bioorganic & Medicinal Chemistry · 2012 · 150 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +6

Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans

Yoshinobu Nakamaru, Yoshiharu Hayashi, Ruriko Ikegawa et al. · Xenobiotica · 2013 · 56 citations

Medicine, Pharmacokinetics, Pharmacology +12

Mechanosensitive channel functions to alleviate the cell lysis of marine bacterium, <i>Vibrio alginolyticus</i>, by osmotic downshock

Yoshinobu Nakamaru, Yuuichirou Takahashi, Tsutomu Unemoto et al. · FEBS Letters · 1999 · 47 citations

Life Sciences, Microbiology, Physiology +17

Evaluation of Pharmacokinetics, Safety, and Drug‐Drug Interactions of an Oral Suspension of Edaravone in Healthy Adults

H. Shimizu, Yukiko Nishimura, Yoichi Shiide et al. · Clinical Pharmacology in Drug Development · 2021 · 34 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +9

The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats

Takahiro Oguma, Chiaki Kuriyama, Keiko Nakayama et al. · Journal of Pharmacological Sciences · 2015 · 28 citations · Full text

Medicine, Endocrinology, Pharmacology +17